PMID- 30665880
OWN - NLM
STAT- MEDLINE
DCOM- 20200331
LR  - 20200331
IS  - 2452-3186 (Electronic)
IS  - 2452-3186 (Linking)
VI  - 67
IP  - 1
DP  - 2019 Feb
TI  - Immunomagnetic selective donor-derived CD4(+)CCR7(+) T cell depletion procedure 
      for peripheral blood stem cells graft.
PG  - 1-7
LID - S2452-3186(18)30055-2 [pii]
LID - 10.1016/j.retram.2018.11.002 [doi]
AB  - PURPOSE OF THE STUDY: While acute graft-versus-host-disease (GVHD) is a T 
      cell-mediated disease caused by alloreactive donor T cells, we and others have 
      highlighted that patients who received higher proportion of donor CD4(+) naive 
      and central memory T cells expressing the chemokine receptor 7 (CCR7) more often 
      developed acute GVHD than those who did not. Consequently, we then investigated 
      in vitro the impact of selective CD4(+) CCR7(+) T cell depletion on immune 
      reactions and showed that such a depletion reduced alloreactivity without 
      altering acquired anti-infectious reactions. In order to translate these findings 
      to clinic, we now developed a compliant procedure for a selective reduction of 
      the CD4(+) naive and central memory T cell subset relevant to peripheral blood 
      stem cell (PBSC) allografts. PATIENTS AND METHODS: We performed a two-step 
      immunomagnetic depletion of CD4(+) CCR7(+) T cells from ten G-CSF-mobilized PBSC 
      apheresis samples. RESULTS: A median of 89% (82-94%) of CD4(+) CCR7(+) T cells 
      could be depleted. This allowed a marked reduction of the alloreactive immune 
      response against allogenic dendritic cells compared with unmanipulated cells. The 
      preservation of CD34(+) cell number and the hematopoietic progenitor function 
      were controlled. Functional tests showed that the selection procedure did not 
      interfere with the capacity of pathogen-specific T cells to produce 
      interferon-gamma in response to certain viral pathogens. CONCLUSION: Our results 
      pave the way to a feasible procedure that can be used in patients undergoing 
      allo-hematopoietic cell transplantation and particularly for improving 
      haploidentical transplant results by controlling GVHD, the main immune 
      complication.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Varlet, P
AU  - Varlet P
AD  - Institut d'Immunologie, CHRU Lille, France; Universite de Lille, Inserm U995, 
      LIRIC, Lille, France. Electronic address: pauline.varlet@chru-lille.fr.
FAU - Rogeau, S
AU  - Rogeau S
AD  - Institut d'Immunologie, CHRU Lille, France; Universite de Lille, Inserm U995, 
      LIRIC, Lille, France.
FAU - Trauet, J
AU  - Trauet J
AD  - Institut d'Immunologie, CHRU Lille, France; Universite de Lille, Inserm U995, 
      LIRIC, Lille, France.
FAU - Demaret, J
AU  - Demaret J
AD  - Institut d'Immunologie, CHRU Lille, France; Universite de Lille, Inserm U995, 
      LIRIC, Lille, France.
FAU - Labalette, M
AU  - Labalette M
AD  - Institut d'Immunologie, CHRU Lille, France; Universite de Lille, Inserm U995, 
      LIRIC, Lille, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190119
PL  - France
TA  - Curr Res Transl Med
JT  - Current research in translational medicine
JID - 101681234
RN  - 0 (CCR7 protein, human)
RN  - 0 (Receptors, CCR7)
SB  - IM
MH  - Blood Component Removal/methods
MH  - CD4-Positive T-Lymphocytes/*cytology/immunology/metabolism
MH  - Cell Engineering/methods
MH  - Cells, Cultured
MH  - *Donor Selection
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - Hematologic Neoplasms/immunology/therapy
MH  - Hematopoietic Stem Cell Transplantation/methods
MH  - Humans
MH  - Immunologic Memory
MH  - *Immunomagnetic Separation/methods
MH  - Lymphocyte Depletion/*methods
MH  - Peripheral Blood Stem Cell Transplantation/adverse effects/*methods
MH  - Peripheral Blood Stem Cells/cytology
MH  - Receptors, CCR7/metabolism
MH  - Transplantation Immunology
MH  - Transplantation, Homologous
OTO - NOTNLM
OT  - Graft engineering
OT  - Graft-versus-host disease
OT  - Naive T cells
OT  - Selective T cell depletion
OT  - T-Lymphocyte Subsets
EDAT- 2019/01/23 06:00
MHDA- 2020/04/01 06:00
CRDT- 2019/01/23 06:00
PHST- 2018/10/15 00:00 [received]
PHST- 2018/11/07 00:00 [revised]
PHST- 2018/11/14 00:00 [accepted]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2020/04/01 06:00 [medline]
PHST- 2019/01/23 06:00 [entrez]
AID - S2452-3186(18)30055-2 [pii]
AID - 10.1016/j.retram.2018.11.002 [doi]
PST - ppublish
SO  - Curr Res Transl Med. 2019 Feb;67(1):1-7. doi: 10.1016/j.retram.2018.11.002. Epub 
      2019 Jan 19.